DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone858-200-0200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$718.50 million
Profitability
Miscellaneous
Employees2,990
Next Earnings Date5/1/2019 (Estimated)
OptionableOptionable
DexCom (NASDAQ:DXCM) Frequently Asked Questions
What is DexCom's stock symbol?
DexCom trades on the NASDAQ under the ticker symbol "DXCM."
How were DexCom's earnings last quarter?
DexCom, Inc. (NASDAQ:DXCM) issued its earnings results on Thursday, February, 21st. The medical device company reported $0.54 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.16 by $0.38. The medical device company had revenue of $338 million for the quarter, compared to analyst estimates of $331.60 million. DexCom had a negative return on equity of 2.89% and a net margin of 4.72%. The business's revenue was up 52.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.10 earnings per share. View DexCom's Earnings History.
When is DexCom's next earnings date?
What guidance has DexCom issued on next quarter's earnings?
DexCom updated its FY 2019 earnings guidance on Monday, January, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.175-1.225 billion, compared to the consensus revenue estimate of $1.18 billion.DexCom also updated its FY 2018 guidance to EPS.
What price target have analysts set for DXCM?
19 analysts have issued 12-month price targets for DexCom's stock. Their forecasts range from $125.00 to $175.00. On average, they anticipate DexCom's stock price to reach $147.8667 in the next year. This suggests a possible upside of 8.0% from the stock's current price. View Analyst Price Targets for DexCom.
What is the consensus analysts' recommendation for DexCom?
19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 6 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DexCom.
What are Wall Street analysts saying about DexCom stock?
Here are some recent quotes from research analysts about DexCom stock:
- 1. Stephens analysts commented, "We rate uniQure Overweight. uniQure focuses on the development of gene therapy products for patients suffering from severe genetic diseases. uniQure is in Phase 3 development for the treatment of hemophilia B with AMT-061, and has additional preclinical programs for Huntington’s disease, hemophilia A and cardiovascular disease." (8/23/2018)
- 2. According to Zacks Investment Research, "Dexcom’s is well positioned in the MedTech space, courtesy of solid contribution from Sensor revenues, Transmitter revenues and Receiver revenues in the last few quarters. The glucose monitoring market represents significant commercial opportunity for DexCom. The company’s solid foothold in the international markets, especially Germany, broad spectrum of products and strategic collaborations, are promising. On the flip side, Dexcom’s share price movement in the past year has been unimpressive. Cutthroat competition in the market for blood & glucose monitoring devices is a headwind for DexCom at the moment. We believe the company’s margins will continue to be under pressure in the coming quarters, owing to high product development costs and rising expenditures on research & development. Lower expected margins on transmitter sales are also a cause of concern." (3/16/2018)
Has DexCom been receiving favorable news coverage?
News headlines about DXCM stock have been trending positive on Friday, InfoTrie Sentiment reports. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. DexCom earned a news impact score of 2.7 on InfoTrie's scale. They also gave news coverage about the medical device company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future.
Who are some of DexCom's key competitors?
Some companies that are related to DexCom include Baxter International (BAX), FRESENIUS SE &/S (FSNUY), ABIOMED (ABMD), ResMed (RMD), Teleflex (TFX), Hill-Rom (HRC), ICU Medical (ICUI), Penumbra (PEN), Insulet (PODD), Novocure (NVCR), Globus Medical (GMED), Haemonetics (HAE), Integra Lifesciences (IART), Cantel Medical (CMD) and Merit Medical Systems (MMSI).
What other stocks do shareholders of DexCom own?
Who are DexCom's key executives?
DexCom's management team includes the folowing people:
- Mr. Kevin R. Sayer, Exec. Chairman, CEO & Pres (Age 61)
- Mr. Quentin S. Blackford, Exec. VP & CFO (Age 40)
- Mr. Steven R. Pacelli, Exec. VP of Strategy & Corp. Devel. (Age 47)
- Mr. Andrew K. Balo, Exec. VP of Clinical Affairs, Regulatory Strategies & Global Access (Age 71)
- Mr. Richard B. Doubleday, Exec. VP & Chief Commercial Officer (Age 56)
Who are DexCom's major shareholders?
DexCom's stock is owned by many different of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (5.55%), Brown Advisory Inc. (3.30%), Geode Capital Management LLC (1.17%), Mackenzie Financial Corp (0.86%), Two Sigma Investments LP (0.82%) and Two Sigma Advisers LP (0.78%). Company insiders that own DexCom stock include Andrew K Balo, Barbara Kahn, Donald Abbey, Eric Topol, Heather S Ace, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Jess Roper, John Lister, Jorge A Valdes, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Doubleday, Steven R Altman, Steven Robert Pacelli and Terrance H Gregg. View Institutional Ownership Trends for DexCom.
Which institutional investors are selling DexCom stock?
DXCM stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Brown Advisory Inc., Jennison Associates LLC, Frontier Capital Management Co. LLC, TD Asset Management Inc., Castleark Management LLC, Los Angeles Capital Management & Equity Research Inc. and Victory Capital Management Inc.. Company insiders that have sold DexCom company stock in the last year include Andrew K Balo, Barbara Kahn, Donald Abbey, Eric Topol, Heather S Ace, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Doubleday, Steven R Altman, Steven Robert Pacelli and Terrance H Gregg. View Insider Buying and Selling for DexCom.
Which institutional investors are buying DexCom stock?
DXCM stock was acquired by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Two Sigma Investments LP, MERIAN GLOBAL INVESTORS UK Ltd, 1832 Asset Management L.P., Eagle Asset Management Inc., Bank of Nova Scotia, Westfield Capital Management Co. LP and Broadfin Capital LLC. View Insider Buying and Selling for DexCom.
How do I buy shares of DexCom?
Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is DexCom's stock price today?
One share of DXCM stock can currently be purchased for approximately $136.86.
How big of a company is DexCom?
DexCom has a market capitalization of $12.16 billion and generates $718.50 million in revenue each year. The medical device company earns $-50,200,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. DexCom employs 2,990 workers across the globe.
What is DexCom's official website?
How can I contact DexCom?
DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-200-0200 or via email at [email protected]
MarketBeat Community Rating for DexCom (NASDAQ DXCM)
MarketBeat's community ratings are surveys of what our community members think about DexCom and other stocks. Vote "Outperform" if you believe DXCM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DXCM will underperform the S&P 500 over the long term. You may vote once every thirty days.
